Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation

JAMA - Journal of the American Medical Association

Volumn 317, Issue 10, 2017, Pages 1057-1067

  Xian, Ying ^a,j   O'Brien, Emily C ^a   Liang, Li ^a   Xu, Haolin ^a   Schwamm, Lee H ^b   Fonarow, Gregg C ^c   Bhatt, Deepak L ^d,e   Smith, Eric E ^f   Olson, Dai Wai M ^g   Maisch, Lesley ^h   Hannah, Deidre ⁱ   Lindholm, Brianna ⁱ   Lytle, Barbara L ^a   Pencina, Michael J ^a   Hernandez, Adrian F ^a   Peterson, Eric D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h Patient Investigator   (United States)

ⁱ Patient Investigator   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; FIBRINOLYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ANTIPLATELET THERAPY; FEMALE; HIGH RISK PATIENT; HOSPITAL MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PREVALENCE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ACUTE DISEASE; BLOOD; CLINICAL TRIAL; COMPLICATION; INTERNATIONAL NORMALIZED RATIO; MORTALITY; MULTICENTER STUDY; ODDS RATIO; ORAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX; STROKE; VERY ELDERLY;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL MORTALITY; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; WARFARIN;

EID: 85015907985     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.1371     Document Type: Article

References (34)

1. Meschia JF, Bushnell C, Boden-Albala B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754-3832
2. Mozaffarian D, Benjamin EJ, Go AS, et al;Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-e360
3. Ezekowitz MD, Bridgers SL, James KE, et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327(20): 1406-1412
4. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335(8):540-546
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151
6. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992
7. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891
8. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104
9. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236
10. Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014;129(13):1407-1414
11. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J AmColl Cardiol. 2005;46(9):1729-1736
12. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019-1026
13. ODonnell M, OczkowskiW, Fang J, et al; Investigators of the Registry of the Canadian Stroke Network. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006;5(9):749-754
14. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240
15. Hannah D, Lindholm B, Maisch L. Certain uncertainty: life after stroke from the patients perspective. Circ Cardiovasc Qual Outcomes. 2014;7 (6):968-969
16. Xian Y, OBrien EC, Fonarow GC, et al. Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research: implementing the patient-driven research paradigm to aid decision making in stroke care. Am Heart J. 2015;170(1):36-45, e1-e45
17. Xian Y, Wu J, OBrien EC, et al. Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. BMJ. 2015;351:h3786
18. OBrien EC, Greiner MA, Xian Y, et al. Clinical effectiveness of statin therapy after ischemic stroke: primary results from the statin therapeutic area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. Circulation. 2015;132 (15):1404-1413
19. Fonarow GC, Reeves MJ, Smith EE, et al; GWTG-Stroke Steering Committee and Investigators. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get With the Guidelines-Stroke. Circ Cardiovasc Qual Outcomes. 2010;3(3):291-302
20. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119(1):107-115
21. Xian Y, Fonarow GC, Reeves MJ, et al. Data quality in the American Heart Association Get With the Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. Am Heart J. 2012;163(3):392-398, e1
22. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7): 864-870
23. Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999; 53(1):126-131
24. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607
25. Gage BF, Waterman AD, ShannonW, Boechler M, RichMW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870
26. Stroke Risk in Atrial FibrillationWorking Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39(6):1901-1910
27. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272
28. Ogilvie IM, Newton N, Welner SA, CowellW, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638-645, e4
29. Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J AmColl Cardiol. 2016;67(25):2913-2923
30. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285 (18):2370-2375
31. Kooistra HA, Calf AH, Piersma-Wichers M, et al. Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists. JAMA Intern Med. 2016;176(8):1176-1183
32. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother. 2008;42(4):523-532
33. Man-Son-HingM, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677-685
34. ReevesMJ, Fonarow GC, Smith EE, et al. Representativeness of the Get With the Guidelines-Stroke Registry: comparison of patient and hospital characteristics among Medicare beneficiaries hospitalized with ischemic stroke. Stroke. 2012;43(1):44-49